Category: NEWLY PUBLISHED
Biosimilars: The Evolution of a New Industry (Review)
KEY POINTS The global oncology mAb market is expected to reach around $45 billion by the end of this decade. ...
Liquid Biopsy: The Golden Cancer Diagnostic Test (an Industrial Review)
KEY POINTS The liquid biopsy market is forecasted to grow at a CAGR of 20.6 percent to reach over $3 ...
World’s 10 Top-Selling Orphan Drugs 2018
KEY POINTS Here are the 10 top-selling orphan drugs in terms of their worldwide sales in the previous financial year. ...
[QUIZ] Healthcare Industry Knowledge Assessment
Healthcare Industry Knowledge Assessment How well do you know the healthcare industry? Take this assessment to identify your knowledge of ...
Survey: 150 CEOs on the Most Valuable Job Skill for Mid-stage Healthcare Professionals
KEY POINTS A global survey of 150 healthcare industries CEOs plus 60 CSOs and COOs. Which skill contributed the MOST ...
Top Companies Leading the Rare Disease Drug Discovery (2018)
KEY POINTS Here are the six companies playing on the front foot in the segment of rare diseases drug discovery. ...
10 Potential Drugs in Development for Alzheimer’s Disease (2018)
KEY POINTS Here are the potential Alzheimer’s disease drug candidates in the late stage of clinical development in 2018. Companies ...
FDA Approves Best-Selling Drugs Combo, ‘Venclexta plus Rituxan’ to Treat Two Common Blood Cancers
Venclexta plus Rituxan combo reduced the risk of chronic lymphocytic leukemia (CLL) progression and death in patients by 81 percent compared to the standard-of-care regimen. It is the first oral-based, chemotherapy-free combination which provides an option of fixed treatment duration to CLL patients.
Mylan-Biocon Bags FDA Nod for Biosimilar Drug ‘Fulphila’, Reduces Infection Risk in Cancer Patients
US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.
This New Cancer Drug Signifies ‘No Return of a Rare Blood Cancer’
AstraZeneca’s promising blood cancer drug, moxetumomab pasudotox has shown tumor shrinkage in 75 percent patients with hairy cell leukemia- a rare and chronic form of blood cancer.